Isoliquiritigenin reduces experimental autoimmune prostatitis by facilitating Nrf2 activation and suppressing the NLRP3 inflammasome pathway.

It was found that isoliquiritigenin treatment could reduce the secretion and invasion of pro-inflammatory cytokines in prostate tissue and reduced prostate inflammation and pelvic pain in EAP mice.